{
    "ticker": "EYPT",
    "name": "EyePoint Pharmaceuticals, Inc.",
    "description": "EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of eye diseases. Founded in 2010 and headquartered in Watertown, Massachusetts, EyePoint leverages its proprietary drug delivery systems to improve patient outcomes in ophthalmology. The company's leading product, YUTIQ, is an implant designed to deliver sustained levels of corticosteroid to patients with chronic non-infectious uveitis affecting the posterior segment of the eye. Additionally, EyePoint is advancing its pipeline of therapies, including EYP-1901, a sustained-release treatment for retinal diseases, which aims to reduce the treatment burden on patients and enhance compliance. With a strong emphasis on research and development, EyePoint collaborates with various research institutions and industry partners to explore new treatment avenues and improve existing therapies. The company is committed to addressing the unmet medical needs of patients suffering from debilitating eye conditions, and its vision extends to expanding its product offerings and enhancing its leadership position in the ophthalmic market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Watertown, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.eyepointpharma.com",
    "ceo": "Nancy L. McKinstry",
    "social_media": {
        "twitter": "https://twitter.com/EyePointPharma",
        "linkedin": "https://www.linkedin.com/company/eyepoint-pharmaceuticals"
    },
    "investor_relations": "https://ir.eyepointpharma.com",
    "key_executives": [
        {
            "name": "Nancy L. McKinstry",
            "position": "CEO"
        },
        {
            "name": "David W. F. N. Dey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Therapeutics",
            "products": [
                "YUTIQ",
                "EYP-1901"
            ]
        }
    ],
    "seo": {
        "meta_title": "EyePoint Pharmaceuticals, Inc. | Innovative Eye Disease Treatments",
        "meta_description": "Discover EyePoint Pharmaceuticals, Inc., a leader in biopharmaceuticals focused on innovative treatments for eye diseases. Explore their advanced drug delivery systems and pipeline.",
        "keywords": [
            "EyePoint Pharmaceuticals",
            "Ophthalmology",
            "Eye Disease Treatment",
            "YUTIQ",
            "EYP-1901",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does EyePoint Pharmaceuticals focus on?",
            "answer": "EyePoint Pharmaceuticals focuses on developing innovative therapeutics for the treatment of eye diseases."
        },
        {
            "question": "What is YUTIQ?",
            "answer": "YUTIQ is an implant designed to deliver corticosteroid to treat chronic non-infectious uveitis affecting the posterior segment of the eye."
        },
        {
            "question": "Where is EyePoint Pharmaceuticals headquartered?",
            "answer": "EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts, USA."
        },
        {
            "question": "Who is the CEO of EyePoint Pharmaceuticals?",
            "answer": "Nancy L. McKinstry is the CEO of EyePoint Pharmaceuticals, Inc."
        },
        {
            "question": "When was EyePoint Pharmaceuticals founded?",
            "answer": "EyePoint Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "BMY",
        "REGN",
        "AKRO",
        "NVDA"
    ],
    "related_stocks": [
        "AMGN",
        "ABBV",
        "GILD",
        "VRTX"
    ]
}